Nobuhiro Suzuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nobuhiro Suzuki has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Naoki Hatakeyama
Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, Japan
5 shared publications- Hiroyuki Tsutsumi
Department of Pediatrics Sapporo Medical University School of Medicine Sapporo Japan
3 shared publications - Masaki Yamamoto
Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, Japan
3 shared publications - Tsukasa Hori
Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, Japan
3 shared publications Hiroyuki Tsutsumi
Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, Japan
2 shared publicationsMakoto Yoshida
Department of Pediatrics, Asahikawa Medical College Hospital, Asahikawa, Japan
2 shared publications
Latest Publications
- 28 July 2015
- Published by IOS Press in Journal of Pediatric Infectious Diseases
- Vol. 08 (01) , 043-047
Candida krusei arthritis in a boy with acute lymphoblastic leukemia
Fungal arthritis is a relatively rare complication, which occurs in patients with hematological disease and cancer. Recently non-albicans Candida species have emerged as clinically important agents; however, Candida krusei (C. krusei) arthritis is still rare. We report a 6-year-old boy who developed C. krusei arthritis associated with acute lymphoblastic leukemia. He was given oral fluconazole and broad-spectrum antibiotics prophylactically, but nevertheless, he developed fungemia with C. krusei and subsequently developed arthritis in his right hip. He was successfully treated with liposomal amphotericin B and micafungin combined with surgical drainage. This is the youngest case with C. krusei arthritis.
- 28 July 2015
- Published by IOS Press in Journal of Pediatric Infectious Diseases
- Vol. 08 (01) , 043-047
Candida krusei arthritis in a boy with acute lymphoblastic leukemia
Fungal arthritis is a relatively rare complication, which occurs in patients with hematological disease and cancer. Recently non-albicans Candida species have emerged as clinically important agents; however, Candida krusei (C. krusei) arthritis is still rare. We report a 6-year-old boy who developed C. krusei arthritis associated with acute lymphoblastic leukemia. He was given oral fluconazole and broad-spectrum antibiotics prophylactically, but nevertheless, he developed fungemia with C. krusei and subsequently developed arthritis in his right hip. He was successfully treated with liposomal amphotericin B and micafungin combined with surgical drainage. This is the youngest case with C. krusei arthritis.
- 20 December 2011
- Published by Wiley in Pediatrics International
- Vol. 53 (6) , 1070-1073
Infantile acute promyelocytic leukemia without an RARα rearrangement
- 20 December 2011
- Published by Wiley in Pediatrics International
- Vol. 53 (6) , 1070-1073
Infantile acute promyelocytic leukemia without an RARα rearrangement
- Open Access
- 1 March 2011
- Published by Wiley in Microbiology and Immunology
- Vol. 55 (5) , 328-330
Human cytomegalovirus UL97 D605E polymorphism has a high prevalence in immunocompetent Japanese infants and children
- 1 March 2011
- Published by Wiley in Microbiology and Immunology
- Vol. 55 (5) , 328-330
Open AccessHuman cytomegalovirus UL97 D605E polymorphism has a high prevalence in immunocompetent Japanese infants and children
- 7 October 2009
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 54 (1) , 71-78
Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia Study (JACLS) ALL F‐protocol
Background: Children with acute lymphoblastic leukemia (ALL) who fail to achieve complete remission (CR) after induction therapy (induction failure: IF) have a poor prognosis; however, there have been few prospective studies in patients with IF.Patients and Methods: Between April 1997 and March 2005, 27 of 1,237 leukemic patients (2.2%) failed to achieve CR after four‐ or five‐drug induction therapy. Twenty‐three of these patients entered the F‐protocol study, which mainly consisted of acute‐myeloid‐leukemia‐oriented chemotherapy followed by scheduled hematopoietic cell transplantation (HCT).Results: Seventeen (73.9%) of the 23 patients responded to re‐induction chemotherapy with CR. Of note, 15 (93.8%) of 16 patients with Philadelphia‐chromosome‐negative (non‐Ph+) ALL achieved CR; in contrast, only 2 (28.6%) of 7 Ph+ patients achieved CR. Fourteen (82.4%) of 17 patients remained in CR (CCR) until their scheduled HCT, 12 of the 14 with CCR underwent HCT as scheduled, and 6 patients remain in first CR after a median of 78 months (range, 49–107 months). The 5‐year overall survival (OS) rates of 16 patients with non‐Ph+ and 7 patients with Ph+ were 43.8 ± 12.4% and 14.3 ± 13.2%, respectively (P = 0.012). The 5‐year OS rate of the 17 patients who obtained CR by re‐induction therapy and the 6 who did not were 47.1 ± 12.1% and 0%, respectively (P < 0.001).Conclusion: Acute‐myeloid‐leukemia‐oriented chemotherapy followed by scheduled HCT is a promising treatment strategy for non‐Ph+ ALL patients with IF. Pediatr Blood Cancer 2010; 54:71–78.
- 7 October 2009
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 54 (1) , 71-78
Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia Study (JACLS) ALL F‐protocol
Background: Children with acute lymphoblastic leukemia (ALL) who fail to achieve complete remission (CR) after induction therapy (induction failure: IF) have a poor prognosis; however, there have been few prospective studies in patients with IF.Patients and Methods: Between April 1997 and March 2005, 27 of 1,237 leukemic patients (2.2%) failed to achieve CR after four‐ or five‐drug induction therapy. Twenty‐three of these patients entered the F‐protocol study, which mainly consisted of acute‐myeloid‐leukemia‐oriented chemotherapy followed by scheduled hematopoietic cell transplantation (HCT).Results: Seventeen (73.9%) of the 23 patients responded to re‐induction chemotherapy with CR. Of note, 15 (93.8%) of 16 patients with Philadelphia‐chromosome‐negative (non‐Ph+) ALL achieved CR; in contrast, only 2 (28.6%) of 7 Ph+ patients achieved CR. Fourteen (82.4%) of 17 patients remained in CR (CCR) until their scheduled HCT, 12 of the 14 with CCR underwent HCT as scheduled, and 6 patients remain in first CR after a median of 78 months (range, 49–107 months). The 5‐year overall survival (OS) rates of 16 patients with non‐Ph+ and 7 patients with Ph+ were 43.8 ± 12.4% and 14.3 ± 13.2%, respectively (P = 0.012). The 5‐year OS rate of the 17 patients who obtained CR by re‐induction therapy and the 6 who did not were 47.1 ± 12.1% and 0%, respectively (P < 0.001).Conclusion: Acute‐myeloid‐leukemia‐oriented chemotherapy followed by scheduled HCT is a promising treatment strategy for non‐Ph+ ALL patients with IF. Pediatr Blood Cancer 2010; 54:71–78.
- 1 August 2009
- Published by Elsevier in The Journal of Pediatrics
- Vol. 155 (2) , 235-238.e1
Characteristics of Hemophagocytic Lymphohistiocytosis in Neonates: A Nationwide Survey in Japan
- 1 August 2009
- Published by Elsevier in The Journal of Pediatrics
- Vol. 155 (2) , 235-238.e1
Characteristics of Hemophagocytic Lymphohistiocytosis in Neonates: A Nationwide Survey in Japan
- 19 March 2009
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 53 (2) , 203-205
Treatment of an infant with severe acute refractory immune thrombocytopenic purpura using combination therapy including rituximab
Some infants with acute immune thrombocytopenic purpura (ITP) do not respond to first‐line therapy, and currently there is no consensus on therapy for these refractory cases. We describe a 12‐week‐old infant with acute ITP who was unresponsive to intravenous immunoglobulin and corticosteroid, and developed gastrointestinal bleeding. Several combination therapies were unsuccessful. After four doses of rituximab followed by intravenous immunoglobulin and corticosteroid, his platelet counts gradually increased. Combined therapy which includes rituximab may be a promising treatment for severe acute refractory ITP. Pediatr Blood Cancer 2009;53:203–205.
- 19 March 2009
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 53 (2) , 203-205
Treatment of an infant with severe acute refractory immune thrombocytopenic purpura using combination therapy including rituximab
Some infants with acute immune thrombocytopenic purpura (ITP) do not respond to first‐line therapy, and currently there is no consensus on therapy for these refractory cases. We describe a 12‐week‐old infant with acute ITP who was unresponsive to intravenous immunoglobulin and corticosteroid, and developed gastrointestinal bleeding. Several combination therapies were unsuccessful. After four doses of rituximab followed by intravenous immunoglobulin and corticosteroid, his platelet counts gradually increased. Combined therapy which includes rituximab may be a promising treatment for severe acute refractory ITP. Pediatr Blood Cancer 2009;53:203–205.
- 1 March 2007
- Vol. 48 (3) , 204-11
[Complications in the central nervous system during chemotherapy for childhood acute lymphoblastic leukemia: JACLS ALL-02 study].
We evaluated central nervous system (CNS) complications treated under the ALL-02 protocol of the Japan Association of Childhood Leukemia Study (JACLS) from April 2002 to March 2005. According to NCI Toxicity Criteria, 17 events of grade 3 and 4 CNS complications were reported in 15 out of 541 patients. Out of these CNS complications, leukoencephalopathy was seen in 5 patients; seizure in 5; cerebrovascular disease in 3; conscious disturbance in 2; and hypertensive encephalopathy and reversible posterior leukoencephalopathy syndrome in one patient each. The complications were intensively observed during induction therapy and the last of the early phase chemotherapy. The protocol treatment was stopped or modified in most patients after CNS complications. MRI imaging demonstrated no improvement in one patient with leukoencephalopathy who developed an isolated CNS relapse, while other patients were alive and remain in their first complete remission without any neurological sequelae. Further studies will be required to analyze risk factors for CNS complications during chemotherapy not accompanied by irradiation and to establish alternative treatments after the appearance of such CNS complications.
- 1 March 2007
- Vol. 48 (3) , 204-11
[Complications in the central nervous system during chemotherapy for childhood acute lymphoblastic leukemia: JACLS ALL-02 study].
We evaluated central nervous system (CNS) complications treated under the ALL-02 protocol of the Japan Association of Childhood Leukemia Study (JACLS) from April 2002 to March 2005. According to NCI Toxicity Criteria, 17 events of grade 3 and 4 CNS complications were reported in 15 out of 541 patients. Out of these CNS complications, leukoencephalopathy was seen in 5 patients; seizure in 5; cerebrovascular disease in 3; conscious disturbance in 2; and hypertensive encephalopathy and reversible posterior leukoencephalopathy syndrome in one patient each. The complications were intensively observed during induction therapy and the last of the early phase chemotherapy. The protocol treatment was stopped or modified in most patients after CNS complications. MRI imaging demonstrated no improvement in one patient with leukoencephalopathy who developed an isolated CNS relapse, while other patients were alive and remain in their first complete remission without any neurological sequelae. Further studies will be required to analyze risk factors for CNS complications during chemotherapy not accompanied by irradiation and to establish alternative treatments after the appearance of such CNS complications.
- 1 January 2007
- Published by Springer Nature in International Journal of Hematology
- Vol. 85 (1) , 70-72
Treatment of McLeod Phenotype Chronic Granulomatous Disease with Reduced-Intensity Conditioning and Unrelated-Donor Umbilical Cord Blood Transplantation
Patients with chronic granulomatous disease (CGD) complicated by antimycotics-refractory invasive aspergillosis have an extremely poor prognosis if they cannot undergo allogeneic hematopoietic stem cell transplantation from a suitable related donor while in good clinical condition.We successfully treated a 20-year-old man with very rare McLeod phenotype CGD with reduced-intensity conditioning and unrelated-donor umbilical cord blood transplantation.We postulate that reduced-intensity conditioning—allogeneic hematopoietic stem cell transplantation is a promising therapeutic strategy for patients with CGD even if only unrelated-donor umbilical cord blood is available.
- 1 January 2007
- Published by Springer Nature in International Journal of Hematology
- Vol. 85 (1) , 70-72
Treatment of McLeod Phenotype Chronic Granulomatous Disease with Reduced-Intensity Conditioning and Unrelated-Donor Umbilical Cord Blood Transplantation
Patients with chronic granulomatous disease (CGD) complicated by antimycotics-refractory invasive aspergillosis have an extremely poor prognosis if they cannot undergo allogeneic hematopoietic stem cell transplantation from a suitable related donor while in good clinical condition.We successfully treated a 20-year-old man with very rare McLeod phenotype CGD with reduced-intensity conditioning and unrelated-donor umbilical cord blood transplantation.We postulate that reduced-intensity conditioning—allogeneic hematopoietic stem cell transplantation is a promising therapeutic strategy for patients with CGD even if only unrelated-donor umbilical cord blood is available.
- 10 April 2003
- Published by Wiley in Haemophilia
- Vol. 9 (3) , 340-342
Successful induction of immune tolerance in a patient with haemophilia B with inhibitor
- 10 April 2003
- Published by Wiley in Haemophilia
- Vol. 9 (3) , 340-342
Successful induction of immune tolerance in a patient with haemophilia B with inhibitor
- 1 January 2001
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 18 (3) , 205-210
TRANSPLANTED PERIPHERAL BLOOD STEM CELLS, MOBILIZED BY CHEMOTHERAPY ALONE, CAN INDUCE PERSISTENT HEMATOPOIESIS IN CHILDREN WITH ACUTE LEUKEMIA
Three patients with leukemia were transplanted with peripheral blood stem cells mobilized by intensification or maintenance chemotherapy alone. They maintained persistent reconstituted hematopoiesis for at least 9 years. The experience provides evidence that long-term marrow repopulating cells can be mobilized into the blood to an adequate repopulating extent by chemotherapy alone.
- 1 January 2001
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 18 (3) , 205-210
TRANSPLANTED PERIPHERAL BLOOD STEM CELLS, MOBILIZED BY CHEMOTHERAPY ALONE, CAN INDUCE PERSISTENT HEMATOPOIESIS IN CHILDREN WITH ACUTE LEUKEMIA
Three patients with leukemia were transplanted with peripheral blood stem cells mobilized by intensification or maintenance chemotherapy alone. They maintained persistent reconstituted hematopoiesis for at least 9 years. The experience provides evidence that long-term marrow repopulating cells can be mobilized into the blood to an adequate repopulating extent by chemotherapy alone.